Structure via PubChem · Public domain (PubChem)
insulin aspart
Sign in to saveAlso known as Novolog, Insulin X14, Novolog Penfill, INA-X14, Novolog Innolet, B28-ASP-INSULIN, Aspart Insulin, Aspart
pharmaceutical drug
In the Vinony graph
Within Vinony's link graph, insulin aspart is referenced by 160 other articles, and connects out to metformin, alogliptin and hypoglycemia.
It is catalogued under topics including Chemicals that do not have a ChemSpider ID assigned, Drugboxes which contain changes to verified fields and Drugs with non-standard legal status.
Its subject is documented across 20 Wikipedia language editions.
Chemical data
- Formula
- C256H381N65O79S6
- Molecular weight
- 5826 g/mol
- IUPAC name
- (4S)-5-[(2S)-1-[2-[(2S)-1-[(2S)-1-[(2S)-1-[(2S,3R)-1-[(2S)-1-[(2S)-6-amino-1-[(1S,2R)-1-carboxy-2-hydroxypropyl]imino-1-hydroxyhexan-2-yl]imino-3-carboxy-1-hydroxypropan-2-yl]imino-1,3-dihydroxybutan-2-yl]imino-1-hydroxy-3-(4-hydroxyphenyl)propan-2-yl]imino-1-hydroxy-3-phenylpropan-2-yl]imino-1-hydroxy-3-phenylpropan-2-yl]imino-2-hydroxyethyl]imino-5-carbamimidamido-1-hydroxypentan-2-yl]imino-4-[[2-[[[(1R,6R,12S,15S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,50S,53S,56S,59S,62S,65S,68S,71S,74R,77S,80S,83S,88R)-88-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[(2-amino-1-hydroxyethylidene)amino]-1-hydroxy-3-methylpentylidene]amino]-1-hydroxy-3-methylbutylidene]amino]-4-carboxy-1-hydroxybutylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-6-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-1-hydroxy-3-phenylpropylidene]amino]-1-hydroxy-3-methylbutylidene]amino]-1,4-dihydroxy-4-iminobutylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-(1H-imidazol-5-yl)propylidene]amino]-1-hydroxy-4-methylpentylidene]amino]-77-[(2S)-butan-2-yl]-24,56-bis(2-carboxyethyl)-47-[N-[(1S)-1-carboxy-3-hydroxy-3-iminopropyl]-C-hydroxycarbonimidoyl]-7,10,13,16,19,22,25,28,31,34,37,40,49,52,55,58,61,64,67,70,73,76,79,82,85,87-hexacosahydroxy-83-[(1R)-1-hydroxyethyl]-53-(2-hydroxy-2-iminoethyl)-62-(3-hydroxy-3-iminopropyl)-12,71,80-tris(hydroxymethyl)-33,50,65-tris[(4-hydroxyphenyl)methyl]-15-(1H-imidazol-5-ylmethyl)-27-methyl-18,30,36,59,68-pentakis(2-methylpropyl)-21,39-di(propan-2-yl)-3,4,44,45,90,91-hexathia-8,11,14,17,20,23,26,29,32,35,38,41,48,51,54,57,60,63,66,69,72,75,78,81,84,86-hexacosazabicyclo[72.11.7]dononaconta-7,10,13,16,19,22,25,28,31,34,37,40,48,51,54,57,60,63,66,69,72,75,78,81,84,86-hexacosaen-42-yl]-hydroxymethylidene]amino]-1-hydroxyethylidene]amino]-5-hydroxypentanoic acid
- SMILES
- CC[C@H](C)[C@H]1C(=N[C@H]2CSSC[C@@H](C(=N[C@@H](CSSC[C@@H](C(=NCC(=N[C@H](C(=N[C@H](C(=N[C@H](C(=N[C@H](C(=N[C@H](C(=N[C@H](C(=N[C@H](C(=N[C@H](C(=N[C@H](C(=N[C@H](C(=N[C@@H](CSSC[C@H](N=C([C@@H](N=C([C@@H](N=C([C@@H](N=C([C@@H](N=C([C@@H](N=C([C@@H](N=C([C@@H](N=C([C@@H](N=C2O)CO)O)CC(C)C)O)CC3=CC=C(C=C3)O)O)CCC(=N)O)O)CC(C)C)O)CCC(=O)O)O)CC(=N)O)O)CC4=CC=C(C=C4)O)O)C(=N[C@@H](CC(=N)O)C(=O)O)O)C(=NCC(=N[C@@H](CCC(=O)O)C(=N[C@@H](CCCNC(=N)N)C(=NCC(=N[C@@H](CC5=CC=CC=C5)C(=N[C@@H](CC6=CC=CC=C6)C(=N[C@@H](CC7=CC=C(C=C7)O)C(=N[C@@H]([C@@H](C)O)C(=N[C@@H](CC(=O)O)C(=N[C@@H](CCCCN)C(=N[C@@H]([C@@H](C)O)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)C(C)C)O)CC(C)C)O)CC8=CC=C(C=C8)O)O)CC(C)C)O)C)O)CCC(=O)O)O)C(C)C)O)CC(C)C)O)CC9=CN=CN9)O)CO)O)O)N=C([C@H](CC(C)C)N=C([C@H](CC2=CN=CN2)N=C([C@H](CCC(=N)O)N=C([C@H](CC(=N)O)N=C([C@H](C(C)C)N=C([C@H](CC2=CC=CC=C2)N)O)O)O)O)O)O)C(=N[C@H](C(=N[C@H](C(=N1)O)CO)O)[C@@H](C)O)O)O)N=C([C@H](CCC(=N)O)N=C([C@H](CCC(=O)O)N=C([C@H](C(C)C)N=C([C@H]([C@@H](C)CC)N=C(CN)O)O)O)O)O)O
- InChIKey
- WEDIKSVWBUKTRA-WTKGVUNUSA-N
- XLogP
- 10.8
- Polar surface area
- 2670 Ų
- H-bond donors
- 86
- H-bond acceptors
- 146
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Protein
- First approval
- 1999
- Admin. routes
- parenteral
- Indications
- diabetes mellitus, leukemia, lymphoma, gestational diabetes
via ChEMBL · EBI
Research
1,697 papers- Insulin aspart.Drugs · 1999
- Faster Insulin Aspart: A New Bolus Option for Diabetes Mellitus.Clinical pharmacokinetics · 2019
- Fast-Acting Insulin Aspart: A Review of its Pharmacokinetic and Pharmacodynamic Properties and the Clinical Consequences.Clinical pharmacokinetics · 2020
- [Insulin aspart(NN-X14)].Nihon rinsho. Japanese journal of clinical medicine · 2001
- Pharmacological Properties of Faster-Acting Insulin Aspart.Current diabetes reports · 2017
via PubMed
Wikidata facts
- Mass
- 5832
- Has use
- medication
Show 6 more facts
- chemical formula
- C₂₅₆H₃₈₇N₆₅O₇₉S₆
- legal status (medicine)
- prescription drug
- NCI Thesaurus ID
- C47563
- subject has role
- anti-diabetic medication
- stylized name
- NovoLOG
- has characteristic
- biopharmaceutical
via Wikidata · CC0
Available in 20 languages
- Español
- Français
- Deutsch
- 中文
- 日本語
- Português
- العربية
- Bahasa Indonesia
- Bangla
- Greek
- Nederlands
- Odia
- Polski
- Romanian
- Serbian
- Serbian (Latin)
- simple
- Tiếng Việt
Show 1 more
via Wikidata sitelinks · CC0
Connections
metformin
Entity
alogliptin
Entity
hypoglycemia
Entity
type-1 diabetes
Entity
anti-diabetic medication
Entity
Insulin Therapy
Entity
subcutaneous injection
Entity
NPH insulin
Entity
insulin analog
Entity
ertugliflozin
Entity
World Health Organization
Entity
human pregnancy
Entity
International Standard Book Number
Entity
gene
Entity
allergy
Entity
amino acid
Entity
glucose
Entity
yeast
Entity
public domain
Entity
digital object identifier
Entity